Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
出版年份 2015 全文链接
标题
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
作者
关键词
Insulin, Glucose, HbA1c, Hypoglycemia, Diabetes mellitus, Carbohydrates, Clinical trials, Walking
出版物
PLoS One
Volume 10, Issue 11, Pages e0141085
出版商
Public Library of Science (PLoS)
发表日期
2015-11-07
DOI
10.1371/journal.pone.0141085
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?
- (2014) David Z.I. Cherney et al. Canadian Journal of Diabetes
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
- (2014) Robert R. Henry et al. DIABETES CARE
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
- (2014) Bruce A. Perkins et al. DIABETES CARE
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE
- (2014) J Cuypers et al. ACTA CLINICA BELGICA
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
- (2013) D. Polidori et al. DIABETES CARE
- Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines
- (2013) J. R. Wood et al. DIABETES CARE
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP)
- (2013) Richard M. Bergenstal et al. Diabetes Technology & Therapeutics
- Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
- (2013) Eiji Kurosaki et al. PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
- (2012) S. Mudaliar et al. DIABETES CARE
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
- (2012) G. Luippold et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
- (2012) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis
- (2008) Roger S. Mazze et al. Diabetes Technology & Therapeutics
- The Future of Self-Monitored Blood Glucose: Mean Blood Glucose Versus Glycosylated Hemoglobin
- (2008) Roger Mazze Diabetes Technology & Therapeutics
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now